Grants & Programs

FY2013 Grantees

In fiscal year 2013 (July 1, 2012 to June 30, 2013), the Cancer Research Institute awarded more than $14.6 million to support groundbreaking clinical and laboratory research in cancer immunology and immunotherapy at 55 institutions in 11 countries throughout the world.

Jump to:
Student and Training and Research in Tumor Immunology (START) Grants
CRI Irvington Postdoctoral Fellowships
Clinic and Laboratory Integration Program (CLIP) Grants
Clinical Accelerator Grants
Designated Grants
Patient Care
 

Student Training and Research in Tumor Immunology (STaRT) Grants

Thomas Chia Ting Fung
Sponsor: David Artis, Ph.D.
University of Pennsylvania
Philadelphia, PA
Role of innate lymphoid cell-controlled intestinal barrier function in hepatocellular carcinoma

Alexandria Huynh
Sponsor: Laurence A. Turka, M.D.
Massachusetts General Hospital
Boston, MA
The role of PTEN in regulatory T cell stability and immune surveillance

Thornton William Thompson
Sponsor: David H. Raulet, Ph.D.
University of California, Berkeley
Berkeley, CA
The role of oncogene-induced senescence in promoting anti-tumor immune responses

Jenny Karo
Sponsor: Joseph Sun, Ph.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
Elucidating the regulatory role of CTLA-4 on natural killer cell responses


CRI Irvington Postdoctoral Fellowships

Michele Ardolino, Ph.D.
Sponsor: David H. Raulet, Ph.D.
University of California, Berkeley
Berkeley, CA
MHC-deficient tumors inactivate infiltrating NK cells: A new target for cancer immunotherapy

Paola A. Betancur, Ph.D.
Sponsor: Irving L. Weissman, M.D.
Stanford University School of Medicine
Stanford, CA
In search of the gene regulatory circuitry responsible for the transcriptional upregulation of CD47, the “don’t eat me” signal in cancer cells

Maureen Ann Cox, Ph.D.
Sponsor: Tak W. Mak, Ph.D., D.Sc., F.R.S.C.
The Campbell Family Cancer Research Institute
Toronto, Canada
Investigation of the role of HMGB1 in asbestos-driven inflammation and mesothelioma development

Viviana Cremasco, Ph.D.
Sponsor: Shannon J. Turley, Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Targeted disruption of tumor matrix architecture to restore cancer immunosurveillance

Nicola Gagliana, Ph.D.
Dr. Keith Landesman Memorial Fellow
Sponsor: Richard A. Flavell, Ph.D., FRS
Yale University School of Medicine
New Haven, CT
Targeting Th17 cell plasticity to control colorectal cancer development

Elizabeth Gray, Ph.D.
Sponsor: Daniel B. Stetson, Ph.D.
University of Washington School of Medicine
Seattle, WA
Functional analysis of the interferon stimulatory DNA pathway

Jesse Green, Ph.D.
Sponsor: Alexander Y. Rudensky, Ph.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
Interactions of regulatory T cells with the tumor endothelium and effects on the tumor microenvironment

Yenkel Grinberg-Bleyer, Ph.D.
Sponsor: Sankar Ghosh, Ph.D.
Columbia University
New York, NY
Testing the role of NF-kappa B in tumor immunity through its effect on regulatory T cells

Shengdong Ke, Ph.D.
Sponsor: Robert B. Darnell, M.D., Ph.D.
The Rockefeller University
New York, NY
RNA epigenetic HITS-CLIP—a new approach to understanding leukemia/lymphoma

Kiwook Kim, Ph.D.
Sponsor: John David MacMicking, Ph.D.
Yale University School of Medicine
New Haven, CT
GBP5-NOD2 interactions in gastrointestinal host defense, colitis, and colon cancer

Chan-Wang J. Lio, Ph.D.
Sponsor: Anjana Rao, Ph.D.
La Jolla Institute for Allergy and Immunology
La Jolla, CA
Role of long non-coding RNAs in the development of T cell leukemia

Vincent Christopher Luca, Ph.D.
Sponsor: K. Christopher Garcia, Ph.D.
Stanford University
Stanford, CA
Deconstructing the structural mechanisms of cytokine-mediated JAK activation

Noah Palm, Ph.D.
Sponsor: Richard A. Flavell, Ph.D., FRS
Yale University School of Medicine
New Haven, CT
Role of helminth infections and the commensal microbiota in intestinal inflammation

Giulia Pasqual, Ph.D.
Sponsor: Gabriel D. Victora, Ph.D.
Whitehead Institute for Biomedical Research
Cambridge, MA
In vivo tracking of B cell-T cell interactions in the germinal center

April Price, Ph.D.
Sponsor: Gregory Barton, Ph.D.
University of California, Berkeley
Berkeley, CA
Expression and function of Toll-like receptors in intestinal epithelial cells

Qi Qiao, Ph.D.
Sponsor: Hao Wu, Ph.D.
Children’s Hospital Boston
Boston, MA
Mechanistic elucidation of activation-induced deaminase (AID) in immunity and cancer

Debrup Sengupta, Ph.D.
Sponsor: Peter Cresswell, Ph.D.
Yale University School of Medicine
New Haven, CT
Membrane trafficking events regulating cross presentation

Xiaolei Su, Ph.D.
Sponsor: Ronald D. Vale, Ph.D.
University of California, San Francisco
San Francisco, CA
Mechanisms underlying the dynamic organization of T cell microclusters

Li Tang, Ph.D.
Sponsor: Darrell J. Irvine, Ph.D.
Massachusetts Institute of Technology
Cambridge, MA
T lymphocyte engineering with Interleukin-2-silica nanocapsules for targeted cancer therapy

Mo Xu, Ph.D.
Sponsor: Dan R. Littman, M.D., Ph.D.
NYU Langone Medical Center
New York, NY
Intestinal microbiota-induced Th17 responses in systemic inflammatory disease

Hye Suk Yoon, Ph.D.
Sponsor: Frederick W. Alt, Ph.D.
Children’s Hospital Boston
Boston, MA
Elucidation of V(D)J recombination control elements in the IgH locus

Yina Zhu, Ph.D.
Sponsor: Cornelis Murre, Ph.D.
University of California, San Diego
La Jolla, CA
Mechanisms that underpin the sequestration of the tumor suppressor EBF1 at the nuclear lamina


Clinic and Laboratory Investigation Program (CLIP) Grants

Nina Bhardwaj, M.D., Ph.D.
Mount Sinai School of Medicine
New York, NY
MMP-2 promotes melanoma progression through TLR mediated mechanisms

Jonathan S. Cebon, Ph.D., FRACP
Ludwig Institute for Cancer Research, Melbourne
Heidelberg, Australia
Evaluation of ROPN and SPANX as targets for antigen-specific immunotherapy

Ian Frazer, M.D., FRCPA
University of Queensland
Taringa, Australia
Optimising immunotherapy for squamous cancer

Thomas F. Gajewski, M.D., Ph.D.
University of Chicago
Chicago, IL
Identification of tumor-intrinsic signaling pathways that inhibit host immune responses as potential therapeutic targets to expand the applicability of immunotherapy

W. Martin Kast, Ph.D.
University of Southern California
Los Angeles, CA
Anti-CTLA4 immune modulation following chemoradiation in cervical cancer patients

Hiroyoshi Nishikawa, M.D., Ph.D.
Osaka University
Osaka, Japan
Novel cancer immunotherapy targeting regulatory T cells by anti-CCR4 mAb

Ellen Puré, Ph.D.
University of Pennsylvania
Philadelphia, PA
Adoptive T cell therapy targeted to tumor stroma to treat lung cancer

Jeffrey C. Rathmell, Ph.D.
Duke University Medical Center
Durham, NC
Metabolic immunosuppression of T cells in clear cell renal cell carcinoma and anti-PD-1 therapy
 

Clinical Accelerator Grants

A phase 1 study to evaluate the safety and tolerability of anti-PD-L1 (MEDI4736) in combination with Tremelimumab in subjects with advanced solid tumors

The study sites are:

  • Memorial Sloan Kettering Cancer Center / PI: Jedd Wolchok
  • Roswell Park Cancer Institute / PI: Kunle Odunsi
  • Dana-Farber Cancer Institute / PI: Stephen Hodi
  • University of Pittsburgh / PI: TBD
  • University of California, Los Angeles / PI: Antoni Ribas

Amendment to: Multi-center phase I study of NY-ESO-1 vaccine in combination with ipilimumab in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated (to allow for third arm)

The study sites are:

  • Memorial Sloan Kettering Cancer Center / PI: Jedd Wolchok
  • University of Pittsburgh / PI: John Kirkwood and Hassane Zarour
  • Mount Sinai School of Medicine / PI: Nina Bhardwaj
  • University of Virginia / PI: Craig Slingluff

 

Designated Grants

George Klein, M.D.
Karolinska Institute
Stockholm, Sweden
Studies on Epstein-Barr Virus, oncogenes and tumor suppressor genes, tumor immunology, and inhibition of tumor cell growth by stroma cells

Malcolm A.S. Moore, D.Phil.
Memorial Sloan-Kettering Cancer Center
New York, NY
* Supported by the Gar Reichman Fund of the Cancer Research Institute
The study of hematopoietic stem cells and progenitor populations in normal and cancer cells

2012 William B. Coley Award for Distinguished Research in Basic Immunology
• Richard A. Flavell, Ph.D., FRS, Yale School of Medicine
• Laurie H. Glimcher, M.D. Weill Cornell Medical College
• Kenneth M. Murphy, M.D., Ph.D., Washington University in St. Louis

2012 William B. Coley Award for Distinguished Research in Tumor Immunology
• Carl H. June, M.D., University of Pennsylvania
• Michel Sadelain, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center

2013 AACR-CRI Lloyd J. Old Award in Cancer Immunology
• James P. Allison, Ph.D., The University of Texas at MD Anderson Cancer Center
 

Patient Care

ZERO-The End of Prostate Cancer